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Abstract
Introduction: This paper provides the first detailed analysis of the NIH prevention research 
portfolio for primary and secondary prevention research in humans and related methods research.
Methods: The Office of Disease Prevention developed a taxonomy of 128 topics and applied it to 
11,082 projects representing 91.7% of all new projects and 84.1% of all dollars used for new 
projects awarded using grant and cooperative agreement activity codes that supported research in 
fiscal years 2012–2017. Projects were coded in 2016–2018 and analyzed in 2018.
Results: Only 16.7% of projects and 22.6% of dollars were used for primary and secondary 
prevention research in humans or related methods research. Most of the leading risk factors for 
death and disability in the U.S. were selected as an outcome in <5% of the projects. Many more 
projects included an observational study, or an analysis of existing data, than a randomized 
intervention. These patterns were consistent over time.
Conclusions: The appropriate level of support for primary and secondary prevention research in 
humans from NIH will differ by field and stage of research. The estimates reported here may be 
overestimates, as credit was given for a project even if only a portion of that project addressed 
prevention research. Given that 74% of the variability in county-level life expectancy across the 
U.S. is explained by established risk factors, it seems appropriate to devote additional resources to 
developing and testing interventions to address those risk factors.
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INTRODUCTION
Established in 1986, the Office of Disease Prevention (ODP) is responsible for assessing, 
facilitating, and stimulating research in disease prevention and health promotion across the 
NIH (https://prevention.nih.gov). ODP collaborates with all 27 Institutes and Centers (ICs) 
at NIH to achieve its mission: to improve public health by increasing the scope, quality, 
dissemination, and impact of prevention research supported by NIH. ODP requires a detailed 
understanding of the portfolio of funded prevention research projects to track levels and 
trends in funding in prevention research over time and to identify research areas that may 
benefit from targeted efforts by NIH.
ODP defines prevention research to include primarya and secondaryb prevention research in 
humans and studies of prevention-related methods for use in humans. The ODP definition 
excludes basic and preclinical studies as too distal to be considered primary or secondary 
prevention; Calitz et al.1 made a similar distinction. The ODP definition also excludes 
treatment studies, with five exceptions. Treatment for smoking, drug abuse, alcohol abuse, 
weight loss treatment for overweight/obese populations, and preventing those with suicidal 
ideation or behaviors from committing suicide are considered secondary prevention.
ODP proposed to develop enhanced portfolio analysis tools and processes in its 2014–2018 
strategic plan.2 This paper describes those tools and processes and presents the results of 
applying those tools and processes to characterize new research projects awarded as grants 
and cooperative agreements for fiscal years 2012–2017 (FY12–17).
METHODS
Taxonomy Development
ODP developed a prevention research taxonomy to guide coding of research projects. The 
taxonomy consists of six categories: rationales, exposures, outcomes, populations, designs, 
and types of prevention research. Within each category are topics (Figure 1); one or more 
topics from each category may be selected for a project.
The rationale category reflects the health condition(s) (diseases, disorders, injuries, or 
disabilities) that motivated the study, with 23 topics including many of the leading causes 
(www.cdc.gov/nchs/fastats/leading-causes-of-death.htm) and risk factors3 for death and 
disability in the U.S. The exposure category reflects the independent variable(s) in the study, 
with 40 topics including most of the conditions used for the rationale and many other 
exposures of interest in prevention research. The outcome category constitutes the dependent 
variable(s) in the study, with 41 topics that overlap almost completely with the exposure 
topics. The population category represents the population groups being studied, with 11 
topics. The design category indicates the methodology employed and has seven topics and 
the prevention research category reflects the type of prevention research, with six topics. 
aPrimary prevention includes preventing a new health condition, promoting health in the general population, or identifying risk factors 
for a new health condition.
bSecondary prevention includes preventing progression of disease, preventing recurrence in those with a known health condition, and 
identifying risk factors for progression or recurrence.
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Project staff were trained to select all topics that applied for a given project and it was 
common to have multiple selections in many of the categories.
Identification of Activity Codes
The portfolio analysis was restricted to the NIH extramural (conducted by researchers at 
institutions outside of NIH) research portfolio because it accounts for >80% of all NIH 
spending; in addition, intramural (conducted by researchers who are employed by NIH) 
research abstracts are structured as progress reports whereas extramural research abstracts 
are structured as proposals, making it difficult to use the same methods for both sets of 
abstracts. To determine which extramural projects to include, ODP consulted with staff from 
many of the NIH ICs to identify activity codes likely to support NIH prevention research. 
NIH uses >200 activity codes (https://grants.nih.gov/grants/funding/ac_search_results.htm) 
to identify extramural funding programs, but many are used for purposes other than research. 
Activity codes used for community services, facilities, infrastructure, loan repayment, 
meetings, planning, and training were excluded. Projects supported by contracts were 
excluded because contract abstracts often provided little insight into the nature of the work.
Extramural research is concentrated in the R (research grants), P (program project grants), 
and U (cooperative agreements) activity codes. Twelvec activity codes from these categories 
were included in the portfolio analysis and each had >500 awards during FY12–17 or >$500 
million in awards during FY12–17. To avoid double counting, this study included only new 
awards (type 1), renewals (type 2), and new awards that changed institutes or centers before 
the project had begun (type 9) that were made using these 12 activity codes. For activity 
codes that included both a parent project and subprojects (e.g., large program project grants), 
sampling was done at the subproject level only, also to avoid double counting. For this 
reason, the units of coding and analysis are referred to as projects.
Projects were identified from NIH’s internal grant database, IMPAC II, using the NIH 
Query/View/Report system (https://archives.nih.gov/asites/era/11–25-2015/
nih_and_grantor_agencies/other/query_view_and_report.cfm) to ensure that all type 1, 2, 
and 9 awards made in FY12–17 using the 12 selected activity codes were included.
Identification of Likely Prevention Projects
ODP used machine learning (ML) tools to predict prevention research and non-prevention 
research projects; details on the ML tools are provided elsewhere.4 The ML algorithms were 
trained using the previous FY’s manually coded type 1 R01d projects (training set), and the 
trained algorithms were used to classify each project in the FY of interest (test set). Because 
of random variability in the performance of the algorithms, each algorithm was trained and 
tested five times, each time with a new starting point.
cActivity codes were: R01, R03, R21, R43, R44, R56, P01, P50, U01, U19, U54, and UM1 (https://grants.nih.gov/grants/funding/
ac_search_results.htm).
dR01 projects were used as the training set because the R01 is the oldest and most common grant at NIH. The R01 provides support 
for discrete, health-related research projects that are relevant to the mission of the NIH.
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The initial plan was to code only type 1 R01s; as a result, 100% of the type 1 R01s that were 
classified as prevention research together with a 5% random sample of the remaining type 1 
R01s for FY12–17 were coded. ODP later decided to expand the scope of the portfolio 
analysis to include 11 other activity codes and two other types. To limit the workload, only 
50% of those prevention projects and 5% of those non-prevention projects, as identified by 
the ML algorithms, were coded. All projects were coded in a random order within activity 
code and FY, and coding staff were blind to the ML classifications.
Coding Research Projects
ODP developed a coding form (Figure 1) based on the prevention research taxonomy and a 
detailed coding protocol that provides instructions, definitions, and examples (Appendix). 
Projects were coded using a team-based, consensus-driven approach using the project’s title, 
abstract, and public health relevance sections, hereafter referred to collectively as the 
project’s abstract. To ensure accurate coding across a wide range of prevention research 
topics, all project staff completed an 8-week training program and met standard performance 
criteria before coding. Staff had to achieve 70% agreement with the answer keys for multiple 
sets of training abstracts.
Each member of a team of three research analysts (RAs) read the project’s abstract and 
selected the applicable topics to characterize the project, with instructions to select all topics 
within each category that applied to each project. The team members then discussed their 
coding and reconciled differences to generate a set of consensus codes. When a consensus 
could not be reached, the supervisor was called to adjudicate. If the issue persisted, the 
project was added to the sample selected for quality control (below). There were enough 
RAs to maintain two to three teams and the composition of the teams was randomized daily 
to avoid consistent triads.
Quality Control
Every week, 10%–20%e of the RA-coded projects were selected at random and, together 
with any projects for which the RAs were unable to achieve consensus, were coded 
independently by three ODP staff blinded to the RA coding, using the same coding process 
and software. After the ODP team reached consensus, the ODP team compared their 
consensus to the RAs’ consensus, and a final set of codes was established for that project, 
with weekly discussions between the two teams. This identified problem areas and ensured 
that the teams were continually aligned over time. The final codes reported for a given 
project were the consensus codes from the RAs, or, if available, the final consensus codes 
after the ODP quality control review.
Statistical Analysis
Kappa statistics were calculated for each of the categories to evaluate consistency among 
RAs and between the RAs and the ODP staff. The method accommodated selection of 
multiple topics within categories5 and was implemented using SAS, version 9. Weighting 
eA higher proportion of projects was selected for quality control at the beginning of the coding process for each activity code, and in 
weeks when the quality control results indicated a Κ <0.70.
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and extrapolation from the sample to the population of projects was completed in Stata/SE, 
version 15, using the svyset command with the pweight and finite population correction 
options. Weights were calculated as the number of projects funded in each (fiscal year X 
activity code X type) combination divided by the number of projects coded in each 
combination, computed separately for prevention and non-prevention projects.
Tests for linear trend were applied to each of the 128 topics, using a Bonferroni corrected 
criteria of p=0.05/128=0.00038. Analysis was completed in 2018.
RESULTS
Interrater Agreement
Coding was completed between October 2015 and February 2018. The monthly weighted 
average Κs between the two sets of consensus codes was 0.86 (range, 0.67–1.00).
Coverage
During FY12–17, NIH issued 63,381 awards for projects using R, P, and U activity codes 
that support research, valued at $32.6 billion. The 12 activity codes selected by ODP 
represented 58,104 (91.7%) of these awards and $25.7 billion (84.1%) of these dollars.
Sensitivity and Specificity for Prevention
Prevention and non-prevention projects were selected for coding and weighted for analysis 
as described above. The ML ensemble had a sensitivity of 70.3% and specificity of 91.1% 
for identifying prevention projects using the ODP definition of prevention.
Projects and Dollars by Topic and Fiscal Year
Figure 2 presents estimated proportions of NIH projects and dollars used for prevention 
research during FY12–17. It is estimated that of all projects and dollars NIH used for 
research grants and cooperative agreements, 16.7% of projects and 22.6% of dollars were 
used to support primary and secondary prevention research in humans or for methods studies 
to support prevention research; 3.2% of projects included prevention-related methods 
research without other primary or secondary prevention research in humans. In FY2014, 
there was a sharp increase in dollars used for cooperative agreements that supported 
prevention research related to clinical trial networks.
Table 1 summarizes the results for coding projects based on their rationale; topic definitions 
are provided in the protocol (Appendix). Mortality was selected as a rationale more often 
than any other topic. Cancer, infectious diseases, maternal/paternal/child health, heart 
disease, mental health, stroke, substance use disorder, neurologic disease, and obesity made 
up the rest of the top ten rationale topics. During FY12–17, cancer declined as a rationale, 
from 22.1% in FY12 to 11.2% in FY17 (p=0.00004). None of the other rationale topics 
presented a significant trend over FY12–17.
Table 2 summarizes the results for coding projects based on their exposures. Genetics was 
selected as an exposure for 26.9% of prevention projects, reflecting the large number of 
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projects that included genetic-risk studies, including genome-wide association studies. 
Education/counseling, medication/device, diet/nutrition, healthcare delivery, infectious 
disease, chemical/toxin, physical activity, tobacco, and substance use disorder made up the 
remaining top ten exposure topics. Topics like infectious disease, chemical/toxin, tobacco, 
substance use disorder, and mental health are used as exposures in studies that group 
participants by their prior history for these topics and examine their risk for onset of a new 
condition or progression of an existing condition. None of the exposure topics presented a 
significant trend over FY12–17.
Table 3 summarizes the results for coding projects based on their outcomes. Cancer, 
infectious disease, healthcare delivery, mental health, health-related quality of life, substance 
use disorder, medication/device, neurologic diseases (excluding Alzheimer disease), heart 
disease, and tobacco completed the top ten outcome topics. Medication/device can be an 
outcome, for example, in a study to determine whether an intervention influences adherence 
to medications, the use of a medical device, or the safety of a medication. Genetics can be an 
outcome, for example, in a study looking at the impact of an intervention on DNA 
methylation. Over FY12–17, there was a decrease in studies that included a cancer outcome, 
from 14.0% to 5.5% (p=0.00012). None of the other outcome topics presented a significant 
trend over FY12–17.
Table 4 summarizes the results for coding projects based on their population foci. Most 
projects did not specify a population focus or focused on the general population and were 
coded as “Adult/Unclear,” representing 71.5% of the projects. Other commonly selected foci 
included youth, urban, older adults, and pregnant or post-partum women. None of the 
population foci topics presented a significant trend over FY12–17.
Table 5 summarizes the results for coding projects based on their research design. 
Observational studies were included in 63.3% of projects, whereas an analysis of existing 
data was included in 43.4%, and methods research was included in 23.9%. Only 18.2% of 
prevention projects included a randomized intervention. None of the research design topics 
presented a significant trend over FY12–17.
Table 6 summarizes the results for coding projects based on their type of prevention 
research. Primary prevention was the most common type of prevention research, included in 
66.1% of projects. Methods research and secondary prevention were also common, included 
in 23.3% and 19.2% of projects, respectively. None of the type of prevention research topics 
presented a significant trend over FY12–17.
DISCUSSION
Current Findings
During FY12–17, ODP estimates that 16.7% of projects and 22.6% of dollars awarded by 
NIH through research grants or cooperative agreements were used to support primary and 
secondary prevention research in humans, together with methods studies to support that 
research. A question for NIH and for the research community is whether these proportions 
are appropriate. There is no agreed upon answer to this question, and the need for prevention 
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research in humans is variable depending on the stage of research for a given area (e.g., 
mechanistic research, development of measures, identification of risk factors, intervention 
development). NIH must also balance the needs of many areas of science as it seeks to fulfill 
its mission of seeking fundamental knowledge about the nature and behavior of living 
systems and applying that knowledge to enhance health, lengthen life, and reduce illness and 
disability. Advancing opportunities in biomedical research in health promotion and disease 
prevention is one of three key targets in the NIH-Wide Strategic Plan (www.nih.gov/news-
events/news-releases/nih-unveils-fy2016–2020-strategic-plan) and the data presented here 
will inform the conversation about the appropriate level of support for prevention research.
A recent report from the Global Burden of Disease project indicates that 74% of the county-
level variability in life expectancy in the can be attributed to well-established risk factors for 
disease, that most of the association between socioeconomic and race/ethnicity factors and 
life expectancy is mediated through those risk factors, and that the addition of healthcare 
factors does not account for additional variation.6 This finding, building on earlier studies 
also pointing to the important role of well-established risk factors across diseases,7 presents 
a strong case for directing a meaningful fraction of the nation’s biomedical research and 
healthcare resources towards addressing those risk factors. As many chronic diseases have 
the same or similar risk factors, the research community should keep that in mind as it 
considers whether the fraction of NIH resources devoted to prevention research is 
appropriate.
The topics that were selected for rationale by more than 5% of the projects in the prevention 
portfolio included many of the leading causes of death and established risk factors. Other 
risk factors that might be expected were not eligible (e.g., diet/nutrition, physical activity), 
because rationale topics were limited to health conditions with only five exceptions.e The 
rank order of the topics reflects the funding decisions of the ICs, which in turn reflect the 
scientific merit of the applications and the programmatic priorities of the ICs. Importantly, 
the rank ordering does not reflect any a priori agreement among or within the ICs to make 
their allocations according to this or any other schema, and the ordering would vary 
considerably if presented by the ICs.
The exposures selected for prevention projects were not widely distributed across the 41 
topics that were included in the taxonomy. The results show 57.3% of the abstracts identified 
at least one exposure as other/unclear, and only four topics were selected for at least 5% of 
the prevention portfolio. This highlights a limitation of this approach, and so additional 
topics within the ODP exposure category may be required going forward.
The outcomes reported for prevention projects were widely distributed, reflecting the wide 
range of health conditions and health behaviors of interest to prevention researchers 
supported by NIH. Notably, the single most preventable cause of death and disability, 
tobacco, was selected for only 5.1% of the prevention research portfolio, and many of the 
other leading risk factors were selected for less than 5% of the portfolio (e.g., alcohol, 
obesity, diet/nutrition, physical activity).
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The vast majority of projects did not point to any specific group as a population focus and 
instead addressed the general adult population. Many included some of the population foci, 
but did not identify them as a special target.
The high proportion of studies that included an observational study (63.3%), an analysis of 
existing data (43.4%), or methods research (23.9%), compared with the significantly lower 
proportion that included a randomized intervention (18.2%), was surprising. Because so 
much is already known about the risk and protective factors that explain a large fraction of 
the variation in death, or life expectancy,6 across diseases, the nation would be well served 
by having more of NIH’s prevention resources focused on applying that knowledge to the 
development and testing of interventions to prevent the leading causes of death by 
addressing those risk and protective factors.
Primary prevention was by far the most common type of prevention research in the portfolio, 
at 62.3%, whereas methods research and secondary prevention represented smaller, but still 
substantial fractions, at 26.2% and 18.1%. Studies focused on screening were much less 
common, particularly screening for risk factors. This finding is consistent with reports from 
the U.S. Preventive Services Task Force which regularly call for more evidence on screening 
for preventable conditions, particularly related to screening for cancer.8
Comparison with Previous Studies
Calitz et al.1 published a report in the American Journal of Preventive Medicine in 2015 on 
NIH funding for behavioral interventions to prevent chronic diseases. Some of their results 
were very different from the results presented here; for example, they reported that 21% and 
70% of prevention awards were primary and secondary prevention, respectively, where this 
paper reports essentially the opposite. Other results were similar; for example, they reported 
that 7% and 4% of prevention awards were for tobacco and alcohol, respectively, whereas 
this paper reports 5% for each as an outcome. The two studies used very different methods, 
so it is not surprising that the results were often different. They drew their data only from the 
NIH Research Portfolio Online Reporting Tools for Expenditures and Results Tool 
(RePORTER), a public-facing research portfolio online reporting toolf; this study drew data 
from NIH’s internal grant database, IMPAC II, which is more complete. They selected 
projects from FY2010 to FY2012; this study drew data from FY12 to FY17. They drew data 
from only eight of the 27 NIH ICs; this study included all 27. They coded awards identified 
by RePORTER as human subjects prevention studies; this study selected projects using ML 
tools. They included all activity codes; this study was restricted to 11 activity codes that 
represented most of the NIH research projects supported by grants and contracts.
Limitations
The authors made no attempt to ascertain the proportion of a project’s proposed activities 
that was focused on a particular topic. Instead, if the text of the abstract met the criteria for a 
topic, that topic was selected for that project. To illustrate, if an abstract had four specific 
aims, and at least one of them qualified as prevention research under ODP’s definition, that 
fhttps://projectreporter.nih.gov/reporter.cfm
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project was coded as a prevention project, even if many of the activities described in the 
abstract did not qualify as prevention research. The authors understood from the outset that 
this would mean that the results might overstate the level of prevention research, or the level 
of any other topic, but judged that parsing the proportion of a project that was focused on a 
particular topic based on the abstract alone was impossible. As a result, the figures reported 
in Table 1 for the proportion of the total number of projects and dollars for projects that were 
coded as prevention (16.7% and 22.6% respectively) should be viewed as an upper bound 
rather than as exact estimates. Fortunately, this limitation is less likely to affect the rank 
ordering of topics within categories.
Another limitation is that the portfolio analysis focused exclusively on the extramural 
research program at NIH, and within that program, on grants and cooperative agreements. 
These activity codes encompass most of the primary and secondary prevention research in 
humans supported by NIH, but not all of it. Some Institutes use both contracts and their 
intramural research program to support prevention research, including some of the important 
vaccine research supported by NIH. The intramural research program represented 10.9% of 
the FY17 NIH budget, and contracts represented 5.9%. However, because only a fraction of 
the funds used to support intramural research and contracts is used for primary and 
secondary prevention research in humans, excluding these projects is unlikely to have biased 
the characterization of the NIH prevention research portfolio reported here.
Another limitation is that the taxonomy included only 128 topics and it is not possible to 
report on any topics that were not included. The data presented here suggest that there were 
missing topics for exposure, but that may also be true for other categories.
NEXT STEPS
This paper provides the most detailed and carefully validated analysis of NIH’s prevention 
portfolio ever conducted. ODP looks forward to a robust discussion with colleagues at NIH 
and with the prevention research community regarding the priorities suggested by these 
findings. One obvious discussion point is whether NIH is investing too little in prevention 
research generally, and in preventive intervention trials in particular. Another is whether the 
observed rank ordering of rationale and outcome topics is appropriate, and whether they 
align sufficiently with the leading and actual causes of death and disability in the U.S.
From the outset, ODP recognized that manual coding would be impractical for the entire 
NIH portfolio. Factors, such as human error, may lead to inconsistencies in coding across 
coders and time. In collaboration with the NIH Office of Portfolio Analysis, ODP will use 
the ML tools to evaluate the sensitivity and specificity for each of the topics included in the 
taxonomy. ODP will continue to apply its methods as new grants are funded. ODP will also 
explore the utility of examining submitted applications, not just funded projects.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. 
Abstract coding form.
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Fig. 2. 
(A). Estimated proportion of NIH projects for grants and collaborative agreements that were 
used to support primary and secondary prevention research in humans, as well as prevention 
related methods research, Fiscal Year 2012–2017. (B). Estimated proportion of NIH dollars 
for grants and collaborative agreements that were used to support primary and secondary 
prevention research in humans, as well as prevention related methods research, Fiscal Year 
2012–2017.
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Table 1.
Estimated Proportion of Projects by Topic and Fiscal Year (FY) Based on Their Rationalesa.
Rank Topic FY2012
%
(95% CI)
FY2013
%
(95% CI)
FY2014
%
(95% CI)
FY2015
%
(95% CI)
FY2016
%
(95% CI)
FY2017
%
(95% CI)
Average
%
(95% CI)
p-trendb
1 Mortality 31.3
(26.1, 36.9)
22.3
(18.3, 26.8)
34.1
(28.9, 39.8)
27.7
(23.3, 32.6)
28.3
(24.4, 32.4)
23.2
(19.6, 27.2)
28.0
(26.1, 30.0)
0.09415
2 Cancer 22.1
(17.5, 27.6)
20.0
(15.3, 25.7)
20.7
(16.3, 25.9)
17.4
(14.3, 20.9)
15.7
(13.0, 18.7)
11.2
(8.2, 15.0)
17.8
(16.2, 19.7)
0.00004
3 Infectious disease 17.5
(13.7, 22.0)
14.3
(11.2, 18.1)
21.7
(17.2, 27.0)
19.5
(15.7, 23.9)
16.6
(13.2, 20.7)
16.7
(13.7, 20.1)
17.8
(16.2, 19.6)
0.95843
4 Other or unclear 15.9
(12.0, 20.8)
16.1
(12.0, 21.3)
12.1
(9.5, 15.4)
17.7
(13.5, 22.9)
14.0
(10.7, 18.0)
14.9
(10.9, 20.0)
15.1
(13.5, 16.9)
0.77814
5 Maternal/paternal/
child health
12.2
(9.4, 15.6)
13.1
(10.0, 16.9)
12.9
(10.0, 16.4)
11.4
(9.2, 14.2)
13.6
(10.7, 17.1)
16.2
(12.8, 20.4)
13.2
(12.0, 14.6)
0.14479
6 Heart disease 9.3
(6.8, 12.6)
9.8
(7.0, 13.6)
9.3
(6.8, 12.6)
13.0
(9.7, 17.3)
11.5
(8.7, 15.1)
8.6
(6.7, 11.0)
10.2
(9.0, 11.5)
0.67808
7 Mental health 10.4
(7.8, 13.8)
14.7
(10.7, 20.0)
6.0
(4.8, 7.4)
8.2
(6.7, 9.9)
11.3
(8.4, 14.9)
11.4
(8.8, 14.7)
10.2
(9.0, 11.4)
0.91208
8 Substance abuse 8.0
(6.6, 9.7)
8.4
(6.2, 11.2)
8.3
(6.0, 11.4)
9.9
(7.7, 12.7)
6.8
(5.5, 8.4)
12.7
(9.4, 17.0)
9.1
(8.1, 10.2)
0.05303
9 Stroke 7.3
(5.3, 9.9)
7.5
(5.4, 10.5)
8.8
(6.1, 12.6)
10.5
(7.5, 14.4)
9.0
(6.8, 11.8)
8.2
(6.3, 10.6)
8.6
(7.5, 9.8)
0.31031
10 Neurological
disease (not
Alzheimer’s)
5.9
(4.1, 8.6)
5.1
(3.2, 8.1)
7.9
(5.1, 12.0)
9.0
(6.2, 12.9)
9.8
(7.0, 13.4)
9.8
(7.0, 13.6)
8.0
(6.8, 9.3)
0.00480
a
Tabled values are the estimated proportions and 95% CI of NIH projects funded as grants or cooperative agreements that supported primary and 
secondary prevention research in human, as well as related methods research for FY2012–2017, based on the rationales coded for each project. The 
topics are ranked based on average proportion of prevention projects coded for each rationale and the table presents the top ten; the complete table 
is provided in Appendix Table 1.
bWith 128 tests for trend, the test is significant only if p-trend<0.00039.
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Table 2.
Estimated Proportion of Projects by Topic and Fiscal Year (FY) Based on Their Exposuresa.
Rank Topic FY2012
%
(95% CI)
FY2013
%
(95% CI)
FY2014
%
(95% CI)
FY2015
%
(95% CI)
FY2016
%
(95% CI)
FY2017
%
(95% CI)
Average
%
(95% CI)
p-trendb
1 Other or unclear 56.9
(51.6, 62.1)
52.7
(46.9, 58.4)
52.3
(46.7, 57.7)
57.7
(52.5, 62.7)
59.8
(55.2, 64.2)
55.1
(49.8, 60.2)
55.7
(53.5, 57.8)
0.48771
2 Genetics 27.7
(22.8, 33.2)
31.0
(25.5, 37.0)
24.6
(20.1, 29.7)
30.1
(25.1, 35.6)
25.9
(21.8, 30.5)
22.6
(18.8, 27.0)
26.9
(24.9, 28.9)
0.09479
3 Education/
counseling
12.9
(10.9, 15.1)
13.3
(10.6, 16.5)
15.3
(12.5, 18.6)
12.9
(11.0, 15.1)
15.7
(13.5, 18.1)
15.3
(12.4, 18.7)
14.3
(13.2, 15.4)
0.14592
4 Medication/device 6.9
(4.6, 10.2)
7.0
(4.4, 10.8)
15.7
(11.5, 21.2)
8.8
(6.3, 12.2)
7.3
(5.9, 9.0)
11.9
(8.2, 17.0)
9.8
(8.4, 11.4)
0.19599
5 Diet/nutrition 6.5
(4.5, 9.1)
3.9
(2.9, 5.1)
5.7
(3.6, 8.9)
4.4
(3.4, 5.7)
4.9
(3.8, 6.3)
5.6
(3.9, 8.2)
5.2
(4.5, 6.0)
0.76013
6 Healthcare delivery 5.8
(4.0, 8.2)
3.3
(2.4, 4.4)
4.3
(2.7, 6.6)
3.7
(2.8, 4.8)
3.6
(2.7, 4.7)
4.9
(3.2, 7.4)
4.3
(3.6, 5.0)
0.61019
7 Infectious disease 3.3
(1.8, 6.1)
2.0
(1.4, 2.9)
5.9
(3.7, 9.4)
3.6
(2.7, 4.7)
4.4
(2.6, 7.3)
3.1
(2.3, 4.2)
3.8
(3.1, 4.6)
0.69820
8 Policy/built
environment
3.6
(2.7, 4.7)
3.8
(2.8, 5.0)
2.7
(2.0, 3.6)
2.8
(2.1, 3.8)
4.6
(3.6, 5.9)
4.7
(3.6, 6.0)
3.7
(3.3, 4.1)
0.07446
9 Chemical/toxin 2.6
(1.8, 3.6)
3.7
(1.9, 6.8)
4.3
(2.4, 7.5)
3.9
(2.9, 5.2)
2.8
(2.1, 3.9)
2.8
(2.0, 3.8)
3.4
(2.8, 4.1)
0.73134
10 Tobacco 2.4
(1.7, 3.4)
5.2
(2.9, 9.3)
2.3
(1.0, 5.1)
1.5
(0.9, 2.3)
2.3
(1.7, 3.2)
2.4
(1.7, 3.4)
2.6
(2.1, 3.4)
0.08577
a
Tabled values are estimated proportions and 95% CI of NIH projects funded as grants or collaborative agreements that supported primary and 
secondary prevention research in humans, as well as related methods research for FY2012–2017, based on the exposures coded for each project. 
The topics are ranked based on average proportion of prevention projects coded for each exposure and the table presents the top ten; the complete 
table is provided in Appendix Table 2.
bWith 128 tests for trend, the test is significant only if p-trend<0.00039.
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Table 3.
Estimated Proportion of Projects by Topic and Fiscal Year (FY) Based on Their Outcomesa.
Rank Topic FY2012
%
(95% CI)
FY2013
%
(95% CI)
FY2014
%
(95% CI)
FY2015
%
(95% CI)
FY2016
%
(95% CI)
FY2017
%
(95% CI)
Average
%
(95% CI)
p-trendb
1 Other or unclear 59.7
(54.1, 65.0)
62.7
(56.7, 68.2)
60.0
(54.3, 65.4)
61.2
(56.0, 66.2)
62.8
(58.1, 67.3)
71.2
(66.7, 75.4)
62.9
(60.8, 65.0)
0.00395
2 Cancer 14.0
(10.2, 19.0)
14.1
(10.4, 19.0)
13.9
(10.2, 18.5)
12.0
(9.6, 14.9)
11.5
(9.1, 14.4)
5.5
(3.7, 8.0)
11.8
(10.4, 13.3)
0.00012
3 Infectious disease 10.7
(7.5, 15.0)
6.4
(5.1, 8.1)
11.2
(8.2, 15.1)
10.3
(7.7, 13.6)
10.3
(7.5, 13.9)
9.9
(7.7, 12.5)
9.9
(8.7, 11.2)
0.68175
4 Healthcare
delivery
7.7
(5.8, 10.2)
7.1
(5.0, 10.1)
6.2
(5.0, 7.7)
9.5
(7.4, 12.2)
11.1
(8.7, 14.0)
7.7
(5.7, 10.2)
8.2
(7.3, 9.1)
0.14265
5 Mental health 7.4
(5.5, 10.0)
11.3
(7.7, 16.3)
5.5
(3.7, 8.2)
5.9
(4.7, 7.4)
7.6
(5.5, 10.4)
6.8
(4.9, 9.3)
7.3
(6.3, 8.4)
0.22846
6 Health related
quality of life
5.6
(3.8, 8.2)
7.2
(5.0, 10.1)
8.5
(5.8, 12.3)
4.0
(3.1, 5.2)
7.0
(5.6, 8.5)
7.0
(4.7, 10.2)
6.6
(5.7, 7.6)
0.85697
7 Substance abuse 6.5
(5.2, 7.9)
6.7
(4.6, 9.5)
5.5
(3.8, 7.9)
7.1
(5.8, 8.7)
5.9
(4.7, 7.4)
5.7
(3.9, 8.2)
6.2
(5.5, 7.0)
0.58219
8 Medication/device 5.9
(3.4, 10.0)
4.7
(2.4, 8.9)
7.9
(5.1, 12.2)
2.8
(2.0, 3.8)
4.6
(2.7, 7.4)
8.7
(5.7, 13.1)
5.9
(4.7, 7.2)
0.53844
9 Neurological
disease
4.4
(2.7, 7.0)
2.4
(1.6, 3.5)
6.4
(3.8, 10.7)
6.0
(3.7, 9.5)
8.4
(5.8, 12.2)
5.9
(3.7, 9.2)
5.6
(4.6, 6.8)
0.02165
10 Heart disease 4.9
(2.9, 8.4)
6.4
(3.9, 10.4)
3.6
(2.7, 4.6)
6.4
(4.1, 9.8)
7.8
(5.2, 11.5)
4.1
(3.2, 5.3)
5.4
(4.6, 6.5)
0.80328
a
Tabled values are the estimated proportions and 95% CI of NIH projects funded as grants or cooperative agreements that supported primary and 
secondary prevention research in human, as well as related methods research for FY2012–2017, based on the outcomes 21 coded for each project. 
The topics are ranked based on average proportion of prevention projects coded for each outcome and the table presents the top ten; the complete 
table is provided in Appendix Table 3.
bWith 128 tests for trend, the test is significant only if p-trend<0.00039.
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Table 4.
Estimated Proportion of Projects by Topic and Fiscal Year (FY) Based on Their Population Focia.
Topic FY2012
%
(95% CI)
FY2013
%
(95% CI)
FY2014
%
(95% CI)
FY2015
%
(95% CI)
FY2016
%
(95% CI)
FY2017
%
(95% CI)
Average
%
(95% CI)
p-trendb
Adult/unclear 71.2
(66.7, 75.3)
73.0
(68.9, 76.8)
74.6
(70.3, 78.5)
70.1
(65.9, 74.0)
71.8
(68.4, 74.9)
68.5
(63.9, 72.8)
71.5
(69.8, 73.2)
0.20969
Youth (infants, children,
adolescents)
25.2
(21.3, 29.6)
25.7
(22.0, 29.8)
21.3
(18.0, 25.0)
26.5
(22.8, 30.6)
24.6
(21.4, 28.0)
29.2
(24.9, 33.9)
25.4
(23.8, 27.0)
0.18494
Older adults/elderly 7.4
(5.4, 10.0)
9.2
(7.5, 11.2)
8.9
(6.0, 13.0)
7.4
(5.2, 10.3)
11.5
(8.7, 15.1)
11.9
(8.7, 16.1)
9.4
(8.2, 10.6)
0.02378
Urban 9.5
(8.0, 11.4)
9.2
(7.6, 11.2)
8.5
(6.8, 10.5)
10.3
(8.6, 12.2)
10.7
(9.0, 12.7)
7.3
(6.0, 8.9)
9.2
(8.5, 10.0)
0.43888
Pregnant and/or post-
partum women
6.0
(4.2, 8.4)
7.4
(5.2, 10.3)
6.0
(4.3, 8.4)
6.9
(5.0, 9.4)
7.7
(5.6, 10.6)
6.7
(8.2, 5.4)
6.7
(5.9, 7.7)
0.51962
Low income 3.9
(3.0, 5.1)
3.8
(2.8, 5.1)
3.5
(2.7, 4.6)
3.9
(3.0, 5.1)
5.0
(3.9, 6.4)
5.5
(3.7, 8.0)
4.3
(3.7, 4.8)
0.06694
LGBTI 2.0
(1.4, 2.9)
2.6
(1.8, 3.7)
3.3
(1.8, 6.0)
2.4
(1.7, 3.4)
3.0
(2.1, 4.1)
2.5
(1.8, 3.5)
2.6
(2.2, 3.2)
0.46184
People with disabilities 2.1
(1.5, 3.0)
2.6
(1.1, 6.1)
3.0
(1.6, 5.5)
2.3
(1.6, 3.3)
1.7
(1.2, 2.6)
3.2
(1.7, 5.7)
2.5
(2.0, 3.2)
0.73181
Rural 2.4
(1.7, 3.3)
2.2
(1.5, 3.1)
1.8
(1.3, 2.6)
2.0
(1.4, 2.8)
2.4
(1.7, 3.4)
2.9
(2.2, 4.0)
2.3
(2.0, 2.6)
0.29727
Military/veterans 0.9
(0.5, 1.6)
0.9
(0.5, 1.5)
2.0
(0.8, 4.9)
0.7
(0.4, 1.3)
1.7
(1.1, 2.5)
0.8
(0.4, 1.4)
1.2
(0.8, 1.6)
0.94862
Incarcerated/
institutionalized
0.7
(0.4, 1.3)
1.8
(0.5, 6.0)c
0.6
(0.3, 1.0)
0.4
(0.2, 1.0)d
0.8
(0.5, 1.5)
1.2
(0.8, 1.9)
0.9
(0.6, 1.4)
0.98876
a
Tabled values are the estimated proportions and 95% CI of NIH projects funded as grants or cooperative agreements that supported primary and 
secondary prevention research in human, as well as related methods research for FY2012–2017, based on the population foci coded for each 
project. The topics are ranked based on average proportion of prevention projects coded for each population focus.
bWith 128 tests for trend, the test is significant only if p-trend<0.00039.
c
Based on a very small sample.
LGBTI, lesbian, gay, bisexual, transgender, intersex.
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Table 5.
Estimated Proportion of Projects by Topic and Fiscal Year (FY) Based on Their Study Designsa.
Topic FY2012
%
(95% CI)
FY2013
%
(95% CI)
FY2014
%
(95% CI)
FY2015
%
(95% CI)
FY2016
%
(95% CI)
FY2017
%
(95% CI)
Average
%
(95% CI)
p-trendb
Observational study 60.1
(54.7, 65.2)
66.8
(61.3, 71.9)
60.9
(55.4, 66.2)
66.9
(62.1, 71.3)
63.9
(59.7, 67.8)
62.0
(56.5, 67.1)
63.3
(61.2, 65.4)
0.72963
Analysis of existing data 36.4
(31.8, 41.3)
45.4
(39.8, 51.1)
40.0
(35.1, 45.1)
46.1
(41.1, 51.3)
50.7
(46.1, 55.4)
43.2
(38.2, 48.3)
43.4
(41.4, 45.5)
0.01015
Methods research 27.3
(22.4, 32.7)
22.9
(18.2, 28.2)
24.6
(20.1, 29.7)
25.4
(20.7, 30.8)
23.1
(19.2, 27.6)
20.3
(16.1, 25.3)
23.9
(22.0, 26.0)
0.09598
Randomized intervention
study
20.3
(16.5, 24.8)
15.9
(12.7, 19.7)
18.8
(15.0, 23.3)
16.3
(13.8, 19.3)
20.5
(17.6, 23.8)
17.0
(14.0, 20.4)
18.2
(16.7, 19.7)
0.63870
Pilot/feasibility/proof-of-
concept/safety
11.9
(8.9, 15.8)
8.6
(6.3, 11.7)
14.3
(10.8, 18.6)
10.6
(8.0, 14.0)
10.2
(7.8, 13.2)
11.5
(8.1, 16.2)
11.3
(10.0, 12.8)
0.90201
Non-randomized
intervention study
5.3
(4.2, 6.7)
5.1
(3.9, 6.6)
8.3
(5.4, 12.4)
5.0
(3.9, 6.4)
8.2
(6.0, 11.0)
5.4
(3.6, 7.9)
6.2
(5.4, 7.2)
0.49871
Other or unclear 2.7
(1.3, 5.4)
3.4
(2.4, 4.7)
5.0
(3.0, 8.2)
4.8
(2.8, 8.2)
2.4
(1.7, 3.5)
2.3
(1.1, 5.0)
3.5
(2.8, 4.4)
0.50368
a
Tabled values are the estimated proportions and 95% CI of NIH projects funded as grants or cooperative agreements that supported primary and 
secondary prevention research in human, as well as related methods research for FY2012–2017, based on the study designs coded for each project. 
The topics are ranked based on average proportion of prevention projects coded for each study design.
bWith 128 tests for trend, the test is significant only if p-trend<0.00039.
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Table 6.
Estimated Proportion of Projects by Topic and Fiscal Year (FY) Based on Their Type of Prevention Researcha.
Topic FY2012
%
(95% CI)
FY2013
%
(95% CI)
FY2014
%
(95% CI)
FY2015
%
(95% CI)
FY2016
%
(95% CI)
FY2017
%
(95% CI)
Average
%
(95% CI)
p-trendb
Primary preventionc 62.3(56.8, 7.6)
70.9
(65.4, 75.8)
63.8
(58.2, 69.1)
67.8
(62.5, 72.6)
64.2
(59.4, 68.7)
68.3
(62.8, 73.4)
66.1
(64.0, 68.2)
0.46362
Methods research 26.2
(21.4, 31.7)
22.0
(17.4, 27.4)
23.6
(19.2, 28.7)
24.9
(20.2, 30.3)
22.8
(18.9, 27.2)
19.9
(15.7, 24.9)
23.3
(21.3, 25.3)
0.16147
Preventing progression
or recurrence
d,e
18.1
(14.8, 21.9)
18.5
(14.8, 22.8)
22.5
(17.9, 27.7)
15.0
(12.4, 18.0)
21.3
(17.7, 25.3)
19.7
(15.8, 24.4)
19.2
(17.6, 20.9)
0.62051
Screening for early
diseasee
3.8
(2.9, 5.0)
5.3
(4.1, 6.8)
4.8
(3.7, 6.0)
5.9
(4.7, 7.4)
5.6
(4.5, 7.1)
5.4
(3.8, 7.8)
5.1
(4.6, 5.7)
0.10848
Screening for risk
factorsc
1.0
(0.6, 1.7)
0.5
(0.2, 1.0)f
1.1
(0.6, 1.8)
0.5
(0.2, 1.0)f
0.3
(0.1, 0.9)f
0.6
(0.3, 1.1)e
0.7
(0.5, 0.9)
0.08744
a
Tabled values are the estimated proportions and 95% CI of NIH projects funded as grants or cooperative agreements that supported primary and 
secondary prevention research in human, as well as related methods research for FY2012–2017, based on the type of prevention research coded for 
each project. The topics are ranked based on average proportion of prevention projects coded for each type of prevention research.
bWith 128 tests for trend, the test is significant only if p-trend<0.00039.
c
Primary prevention includes preventing a new health condition, promoting health in the general population, or identifying risk factors for a new 
health condition.
d
Preventing progression or recurrence includes preventing progression of a health condition, preventing recurrence in those with a known health 
condition, or identifying risk factors for progression or recurrence.
eSecondary prevention includes preventing progression or recurrence, screening for early disease, and screening for risk factors.
f
Based on a very small sample.
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